Skip to main content
. 2024 Sep 28;23:346. doi: 10.1186/s12933-024-02434-5

Fig. 4.

Fig. 4

Potential preventive and therapeutic strategies for CVD risk in MASLD (Created with BioRender.com). MASLD: metabolic dysfunction-associated steatotic liver disease, CVD: cardiovascular disease, DM: diabetes mellitus, GLP-1: glucagon-like Peptide 1, SGLT-2: sodium glucose-linked transporter 2, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, MASH: metabolic dysfunction-associated steatohepatitis, TZDs: thiazolidinediones